US 10,890,589 B2
Metabolic biomarkers for memory loss
Massimo S. Fiandaca, Millersville, MD (US); Mark E. Mapstone, Pittsford, NY (US); Howard J. Federoff, Bethesda, MD (US); Xiaogang Zhong, College Park, MD (US); and Amrita K. Cheema, Potomac, MD (US)
Assigned to Georgetown University, Washington, DC (US); and University of Rochester, Rochester, NY (US)
Appl. No. 15/313,163
Filed by GEORGETOWN UNIVERSITY, Washington, DC (US); and UNIVERSITY OF ROCHESTER, Rochester, NY (US)
PCT Filed May 27, 2015, PCT No. PCT/US2015/032623
§ 371(c)(1), (2) Date Nov. 22, 2016,
PCT Pub. No. WO2015/183917, PCT Pub. Date Dec. 3, 2015.
Claims priority of provisional application 62/003,367, filed on May 27, 2014.
Prior Publication US 2017/0192018 A1, Jul. 6, 2017
Int. Cl. A61K 38/00 (2006.01); C12Q 1/68 (2018.01); G01N 33/567 (2006.01); G01N 33/68 (2006.01); G01N 33/92 (2006.01)
CPC G01N 33/6896 (2013.01) [G01N 33/92 (2013.01); G01N 2570/00 (2013.01); G01N 2800/28 (2013.01)] 5 Claims
 
1. A method of treating memory impairment in a subject, the method comprising
a) analyzing at least one plasma sample from the subject in a fasting state to determine the concentrations of each component of a set of metabolites, wherein the components comprise C3, phosphocholine (PC) aa C32:0, PC aa C40:5, C5-OH (C3-DC-M), PC ae C34:0, C18:1-OH, PC aa C34:4, PC aa C38:4, C5, PC aa C38:3, lysoPC a C18:0, C10:2, C12:1, C16:2, C10:1, asparagine (Asn) and asymmetric dimethylarginine (ADMA), and
b) administering a treatment for memory impairment to the subject when:
(i) the concentrations of the components C3, PC aa C32:0, PC aa C40:5, C5-OH (C3-DC-M), PC ae C34:0, C18:1-OH, PC aa C34:4, PC aa C38:4, C5, PC aa C38:3, lysoPC a C18:0, C10:2, Asn, and ADMA in the subject's set of metabolites are lower as compared to their concentrations in a set of metabolites from subjects determined to define normal concentrations, and
(ii) the concentrations of the components C12:1, C16:2, and C10:1 in the subject's set of metabolites are higher as compared to their concentrations in the set of metabolites from subjects determined to define normal concentrations.